Overview

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the combination of trametinib and pazopanib in patients with advanced gastrointestinal stromal tumors (GIST).
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborator:
Novartis
Treatments:
Trametinib